Salomoni, P; Condorelli, F; Sweeney, SM; Calabretta, B; (2000) Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects. BLOOD , 96 (2) 676 - 684.
Full text not available from this repository.
BAD, the proapoptotic member of the "BH3-only" subfamily of BCL-2 proteins, is inactivated by phosphorylation at serines 112 and 136 and by sequestration in the cytoplasm where it interacts with members of the 14-3-3 family. In BCR/ABL-expressing cells, BAD is constitutively phosphorylated and mainly cytoplasmic, whereas in cells expressing BCR/ABL mutants unable to protect from apoptosis, BAD is nonphosphorylated. We show here that both the wild-type (WT) and the S112A/ S136A double mutant (DM) BAD are more potent inducers of apoptosis in parental than in BCR/ABL-expressing 32D myeloid precursor cells. Stable lines of parental cells expressing DM BAD could not be established and most clones from WT BAD retrovirus-infected parental cells lost BAD expression. On IL-3 withdrawal from parental 32D cells, BAD was rapidly dephosphorylated by the serine-threonine phosphatase 1 alpha, and localized In the mitochondria, whereas it remained phosphorylated and did not localize to the mitochondria in the cohort of BCR/ABL-expressing cells escaping apoptosis induced by WT BAD. Moreover, these cells showed high levels of BCL-2 and BCL-X-L expression. The cohort of BCR/ABL-expressing cells resistant to apoptosis induced by DM BAD showed only high levels of BCL-2 and BCL-X-L. These findings suggest that BCR/ABL-expressing cells am more versatile than normal hematopoietic progenitors in counteracting the apoptotic potential of BAD, end raise the possibility that tumor cells activate multiple antiapoptotic pathways for survival in the face of death-inducing stimuli. (C) 2000 by The American Society of Hematology.
|Title:||Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects|
|Keywords:||CHRONIC MYELOGENOUS LEUKEMIA, ABL TYROSINE KINASE, BCL-X-L, PROTEIN PHOSPHATASE, CYTOCHROME-C, DEATH AGONIST, APOPTOSIS, PHOSPHORYLATION, TRANSFORMATION, ACTIVATION|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Wolfson Institute and Cancer Institute Administration > Cancer Institute > Research Department of Cancer Biology|
Archive Staff Only: edit this record